USRE39706E1 - Crystalline form of a vitamin D analogue - Google Patents

Crystalline form of a vitamin D analogue Download PDF

Info

Publication number
USRE39706E1
USRE39706E1 US10/986,575 US98657593A USRE39706E US RE39706 E1 USRE39706 E1 US RE39706E1 US 98657593 A US98657593 A US 98657593A US RE39706 E USRE39706 E US RE39706E
Authority
US
United States
Prior art keywords
calcipotriol
pharmaceutical composition
monohydrate
hydrate
calcipotriol monohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US10/986,575
Other languages
English (en)
Inventor
Erik Torngaard Hansen
Niels Smidt Rastrup Andersen
Lene Hoffmeyer Ringborg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10728784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE39706(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Application granted granted Critical
Publication of USRE39706E1 publication Critical patent/USRE39706E1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/02—Apparatus characterised by being constructed of material selected for its chemically-resistant properties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C5/00—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms
    • C07C5/32—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by dehydrogenation with formation of free hydrogen
    • C07C5/321—Catalytic processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C5/00—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms
    • C07C5/32—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by dehydrogenation with formation of free hydrogen
    • C07C5/327—Formation of non-aromatic carbon-to-carbon double bonds only
    • C07C5/333—Catalytic processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C5/00—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms
    • C07C5/32—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by dehydrogenation with formation of free hydrogen
    • C07C5/327—Formation of non-aromatic carbon-to-carbon double bonds only
    • C07C5/333—Catalytic processes
    • C07C5/3335—Catalytic processes with metals
    • C07C5/3337—Catalytic processes with metals of the platinum group
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/02—Apparatus characterised by their chemically-resistant properties
    • B01J2219/0204—Apparatus characterised by their chemically-resistant properties comprising coatings on the surfaces in direct contact with the reactive components
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/02—Apparatus characterised by their chemically-resistant properties
    • B01J2219/0204—Apparatus characterised by their chemically-resistant properties comprising coatings on the surfaces in direct contact with the reactive components
    • B01J2219/0236—Metal based
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/02—Apparatus characterised by their chemically-resistant properties
    • B01J2219/025—Apparatus characterised by their chemically-resistant properties characterised by the construction materials of the reactor vessel proper
    • B01J2219/0277—Metal based
    • B01J2219/0286—Steel
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2523/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00
    • C07C2523/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00 of noble metals
    • C07C2523/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00 of noble metals of the platinum group metals
    • C07C2523/42—Platinum

Definitions

  • the present invention relates to calcipotriol, hydrate—a new crystalline form of calcipotriol—with superior technical properties e.g. in the manufacture of crystal suspension formulations, and with superior stability properties.
  • Calcipotriol (INN) (calcipotriene (USAN), (1 ⁇ ,3 ⁇ ,5Z,7E,22E,24S)-24-Cyclopropyl-9,10-secochola-5,7,10(19), 22-tetraene-1,3,24-triol) is described in International patent application No. PCT/DK86/00081, filing date 14th Jul. 1986, publication No. WO 87/00834.
  • Calcipotriol possesses a remarkable profile of biological activity which has proved very useful e.g. in the topical treatment of psoriasis.
  • crystalline bulk drug is usually subjected to micronization or to a wet milling process in order to reduce the crystal size before the final suspension formulation is prepared.
  • This novel product is the monohydrate of calcipotriol which is perfectly crystalline, stable and wet suited for its use in modern therapy.
  • the anhydrous form of calcipotriol shows a considerable degree of decomposition at this temperature and more than 30% degradation is seen after 12 months storage.
  • Calcipotriol monohydrate may be prepared by dissolving crystalline or non-crystalline calcipotriol in an organic solvent, e.g. ethyl acetate or acetone, followed by the addition of water and optionally a non polar solvent, e.g. hexane.
  • organic solvent e.g. ethyl acetate or acetone
  • non polar solvent e.g. hexane.
  • Calcipotriol monohydrate shall form part of pharmaceutical preparations for topical use, such as creams, ointments, solutions, lotions or gels.
  • concentration of the active ingredient will generally be between 1 and 100 ⁇ g/g.
  • the formulations will be applied one or more times daily.
  • the formulations prepared according to the present invention comprise the active compound in association with a pharmaceutically acceptable vehicle and optionally other therapeutic ingredient(s).
  • vehicle(s) must be “acceptable” in the sense of being compatible with the other ingredients of the preparations and not deleterious to the recipient thereof.
  • Preparations suitable for topical administration include liquid or semi-liquid preparations such as liniments, lotions, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments, pastes or gels; or solutions or suspensions.
  • the preparations of this invention may include one or more additional ingredients such as diluents, buffers, surface active agents, thickeners, lubricants, preservatives, e.g. methyl hydroxybenzoate (including anti-oxidants), emulsifying agents and the like.
  • additional ingredients such as diluents, buffers, surface active agents, thickeners, lubricants, preservatives, e.g. methyl hydroxybenzoate (including anti-oxidants), emulsifying agents and the like.
  • Calcipotriol (2.5 g) was dissolved in ethyl acetate (80 ml) at 50°-80° C. and filtered. The solution was saturated with water, and the product precipitated upon voluntary cooling to room temperature. The resulting slurry was cooled to 0°-10° C. and filtered. The filtered product was dried in vacuo to give calcipotriol, hydrate (2.35 g).
  • Lines characteristic for the hydrate are 1455 (m), 1442 (m), 1330 (w), 1290 (m), 1210 (m), 1085 (m), 907 (m), 895 (m) and 573 (w) cm ⁇ 1 , respectively.
  • Solid state CPMAS 1 CPMAS 13 C NMR The following resonances are characteristic for calcipotriol, hydrate: 147.9, 146.5, 134.8, 130.3, 129.0, 126.5, 116.0, 109.4, 75.5, 68.2, 67.2, 56.9, 55.2, 47.8, 47.5, 42.9, 42.0, 41.3, 30.7, 28.9, 25.6, 23.1, 22.6, 19.5, 14.6, 6.2 and 1.9 ppm, respectively.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
US10/986,575 1993-01-15 1993-01-15 Crystalline form of a vitamin D analogue Expired - Lifetime USRE39706E1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939300763A GB9300763D0 (en) 1993-01-15 1993-01-15 Chemical compound
PCT/DK1994/000011 WO1994015912A1 (en) 1993-01-15 1994-01-07 New crystalline form of a vitamin d analogue

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/491,892 Reissue US5763426A (en) 1993-01-15 1993-01-15 Crystalline form of a vitamin D analogue

Publications (1)

Publication Number Publication Date
USRE39706E1 true USRE39706E1 (en) 2007-06-26

Family

ID=10728784

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/986,575 Expired - Lifetime USRE39706E1 (en) 1993-01-15 1993-01-15 Crystalline form of a vitamin D analogue
US08/491,892 Ceased US5763426A (en) 1993-01-15 1993-01-15 Crystalline form of a vitamin D analogue

Family Applications After (1)

Application Number Title Priority Date Filing Date
US08/491,892 Ceased US5763426A (en) 1993-01-15 1993-01-15 Crystalline form of a vitamin D analogue

Country Status (17)

Country Link
US (2) USRE39706E1 (de)
EP (1) EP0679154B1 (de)
JP (1) JP3729847B2 (de)
KR (1) KR100309751B1 (de)
CN (1) CN1040746C (de)
AT (1) ATE159717T1 (de)
AU (1) AU663249B2 (de)
CA (1) CA2151730C (de)
DE (1) DE69406529T2 (de)
DK (1) DK0679154T3 (de)
ES (1) ES2111287T3 (de)
FI (1) FI108638B (de)
GB (1) GB9300763D0 (de)
GR (1) GR3025668T3 (de)
NZ (1) NZ259679A (de)
RU (1) RU2128646C1 (de)
WO (1) WO1994015912A1 (de)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080234239A1 (en) * 2007-03-15 2008-09-25 Derek Wheeler Topical composition
US20100056644A1 (en) * 2006-11-29 2010-03-04 Nilendu Sen Pharmaceutical compositions containing anhydrous calcipotriene
US20100093676A1 (en) * 2007-03-15 2010-04-15 Wheeler Derek A Polyaphron topical composition with vitamin d
US20110014135A1 (en) * 2005-06-01 2011-01-20 Stiefel Research Australia Pty Ltd Vitamin formulation
US8263580B2 (en) 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
US20130023501A1 (en) * 2009-12-22 2013-01-24 Leo Pharma A/S Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
US9549896B2 (en) 2007-06-26 2017-01-24 Drug Delivery Solutions Limited Bioerodible patch comprising a polyaphron dispersion
US9610245B2 (en) 2011-03-14 2017-04-04 Drug Delivery Solutions Limited Ophthalmic composition
US11696919B2 (en) 2018-03-19 2023-07-11 MC2 Therapeutics Limited Topical composition

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU710931B2 (en) * 1996-02-28 1999-09-30 Sumitomo Pharmaceuticals Company, Limited Crystalline vitamin D derivative
PT3146969T (pt) 1999-04-23 2018-10-18 Leo Pharma As Composição farmacêutica para aplicação dérmica para uso no tratamento da psoríase compreendendo vitamina d e um corticosteroide
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
US7351869B2 (en) * 2002-11-18 2008-04-01 Teva Pharmaceutical Industries Ltd Crystallization method for purification of calcipotriene
MY139521A (en) * 2004-03-18 2009-10-30 Leo Pharma As Stereoselective synthesis of vitamin d analogues
FR2871696B1 (fr) * 2004-06-17 2006-11-10 Galderma Sa Composition topique pour le traitement du psoriasis
TWI318203B (en) * 2004-09-01 2009-12-11 Leo Pharma As Epimerization of allylic alcohols
ES2353482T3 (es) * 2006-02-10 2011-03-02 Amgen, Inc Formas hidrato de amg706.
DE06722936T8 (de) * 2006-03-17 2008-06-05 Leo Pharma A/S Isomerisation pharmazeutischer zwischenprodukte
CA2670425A1 (en) * 2006-08-29 2008-03-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions including vitamin d and corticosteroid
ES2272198B1 (es) * 2006-12-28 2008-06-01 Laboratorios Viñas S.A. Procedimiento para la obtencion de hidrato de calcipotriol.
WO2009137066A1 (en) * 2008-05-08 2009-11-12 United Therapeutics Corporation Treprostinil monohydrate
WO2011002756A2 (en) * 2009-07-01 2011-01-06 Vitamin Derivatives, Inc. Vitamin d compounds and methods for preparing same
US9254296B2 (en) 2009-12-22 2016-02-09 Leo Pharma A/S Pharmaceutical composition comprising vitamin D analogue and cosolvent-surfactant mixture
AU2010335655B2 (en) * 2009-12-22 2015-03-05 Leo Pharma A/S Calcipotriol monohydrate nanocrystals
RU2560677C2 (ru) 2009-12-22 2015-08-20 Лео Фарма А/С Кожная композиция, включающая аналог витамина d и смесь растворителя и поверхностно-активных веществ
MX2012007227A (es) * 2009-12-22 2012-07-30 Leo Pharma As Composicion farmaceutica que comprende analogo de vitamina d y mezcla de cosolvente-tensioactivo.
CN102939078B (zh) 2010-06-11 2014-12-24 利奥制药有限公司 含有维生素d类似物和皮质类固醇的药用喷雾剂组合物
EP2688560A2 (de) 2011-03-24 2014-01-29 Leo Pharma A/S Zusammensetzung aus lipidnanopartikeln und einem kortikosteroid oder vitamin-d-derivat
JP5652723B2 (ja) * 2012-08-17 2015-01-14 フォーモサ・ラボラトリーズ・インコーポレーテッド マキサカルシトールの新しい結晶形態
CN103724162A (zh) * 2014-01-07 2014-04-16 成都医路康医学技术服务有限公司 一种银屑病治疗药物卡泊三醇溶剂化物的制备方法
MA41818A (fr) 2015-03-27 2018-01-30 Leo Pharma As Timbre à micro-aiguilles pour administration d'un principe actif à la peau

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4435325A (en) * 1979-05-23 1984-03-06 Roussel Uclaf 1α,25α-Dihydroxy-cholecalciferol and methods for the production thereof
JPS59104358A (ja) 1982-12-03 1984-06-16 Teijin Ltd １α，２４−ジヒドロキシコレカルシフエロ−ルの一水塩及びその製造法
WO1987000834A1 (en) * 1985-08-02 1987-02-12 Leo Pharmaceutical Products Ltd. A/S Novel vitamin d analogues
US5292727A (en) * 1990-03-01 1994-03-08 Leo Pharmaceutical Products Ltd. Use of the treatment of acne

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4435325A (en) * 1979-05-23 1984-03-06 Roussel Uclaf 1α,25α-Dihydroxy-cholecalciferol and methods for the production thereof
JPS59104358A (ja) 1982-12-03 1984-06-16 Teijin Ltd １α，２４−ジヒドロキシコレカルシフエロ−ルの一水塩及びその製造法
WO1987000834A1 (en) * 1985-08-02 1987-02-12 Leo Pharmaceutical Products Ltd. A/S Novel vitamin d analogues
US4866048A (en) * 1985-08-02 1989-09-12 Leo Pharmaceutical Products Ltd. Novel vitamin D analogues
US5292727A (en) * 1990-03-01 1994-03-08 Leo Pharmaceutical Products Ltd. Use of the treatment of acne

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Bagot et al., "Immunosuppressive effects of 1,25-dihydroxyvitamin D3 analog (Calcipotriol) on epidermal cells". Chemical Abstracts, vol. 119, No. 5, Aug. 2, 1993, Abstract No. 41719, p. 182, col. 1, see abstract and Proc. Workshop Vitamin D (8th) 1991, pp. 518-519. *
Braeutigam et al., "Effects of calcipotriol (MC903) and calcitriol after topical application on the skin of hairless rats. Much lower effect of calcipotriol on systemic calcium homeostasis". Chemical Abstracts vol. 117, No. 21, Nov. 23, 1992, abstract #205159, p. 93, col. 1, see abstract & Skin Pharmacol. vol. 5, No. 2, 1992, pp. 87-92. *
Kragblle et al., "Vitamin D analogs in the treatment of psoriasis". Chemical Abstracts, vol. 116, No. 25, Jun. 22, 1992, abstract No. 248622, p. 90, col. 1, see abstract & J. Cell. Biochem. vol. 49, No. 1, 1992, pp. 46-52. *
Larsen et al., "Structure and absolute configuration of a monohydrate of calcipotriol (1.alpha.,3,5Z,7E,22E,24S)-24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol", Acta Crystallographica, Section C, Crystal Structure Communications, vol. 49, No. 3, 1993, pp. 618-621, see the whole document. *
Thavarajah et al. "1,25(OH)2D3 and Calcipotriol (MC903) have similar effects on the induction of osteoclast-like cell formation in human bone marrow cultures". Biochemical and Biophysical Research Communications, vol. 171, No. 3, Sep. 28, 1990, pp. 1056-1063. *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263580B2 (en) 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
US20110014135A1 (en) * 2005-06-01 2011-01-20 Stiefel Research Australia Pty Ltd Vitamin formulation
US8298515B2 (en) 2005-06-01 2012-10-30 Stiefel Research Australia Pty Ltd. Vitamin formulation
US8629128B2 (en) 2005-06-01 2014-01-14 Stiefel West Coast, Llc Vitamin formulation
US20100056644A1 (en) * 2006-11-29 2010-03-04 Nilendu Sen Pharmaceutical compositions containing anhydrous calcipotriene
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
US20100093676A1 (en) * 2007-03-15 2010-04-15 Wheeler Derek A Polyaphron topical composition with vitamin d
US20080234239A1 (en) * 2007-03-15 2008-09-25 Derek Wheeler Topical composition
US11065195B2 (en) 2007-03-15 2021-07-20 MC2 Therapeutics Limited Topical composition
US9549896B2 (en) 2007-06-26 2017-01-24 Drug Delivery Solutions Limited Bioerodible patch comprising a polyaphron dispersion
US20130023501A1 (en) * 2009-12-22 2013-01-24 Leo Pharma A/S Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
US10154959B1 (en) 2011-03-14 2018-12-18 Drug Delivery Solutions Limited Ophthalmic composition containing a polyaphron dispersion
US9610245B2 (en) 2011-03-14 2017-04-04 Drug Delivery Solutions Limited Ophthalmic composition
US11696919B2 (en) 2018-03-19 2023-07-11 MC2 Therapeutics Limited Topical composition

Also Published As

Publication number Publication date
CA2151730C (en) 2005-01-04
JPH08505612A (ja) 1996-06-18
CN1040746C (zh) 1998-11-18
RU2128646C1 (ru) 1999-04-10
DE69406529T2 (de) 1998-05-28
DK0679154T3 (da) 1998-03-30
WO1994015912A1 (en) 1994-07-21
FI952797A0 (fi) 1995-06-07
FI952797A (fi) 1995-06-07
EP0679154A1 (de) 1995-11-02
KR100309751B1 (ko) 2002-11-08
ATE159717T1 (de) 1997-11-15
FI108638B (fi) 2002-02-28
AU5857394A (en) 1994-08-15
AU663249B2 (en) 1995-09-28
RU95116650A (ru) 1997-06-10
CA2151730A1 (en) 1994-07-21
JP3729847B2 (ja) 2005-12-21
GR3025668T3 (en) 1998-03-31
EP0679154B1 (de) 1997-10-29
CN1115979A (zh) 1996-01-31
KR950704249A (ko) 1995-11-17
ES2111287T3 (es) 1998-03-01
US5763426A (en) 1998-06-09
NZ259679A (en) 1996-11-26
GB9300763D0 (en) 1993-03-03
DE69406529D1 (de) 1997-12-04

Similar Documents

Publication Publication Date Title
USRE39706E1 (en) Crystalline form of a vitamin D analogue
EP3689855A1 (de) Kristalle
JPS5890599A (ja) ステロイド化合物
JPH02191255A (ja) トラセミドの安定な変態の製法
PT2503005E (pt) 17alfa-propionato de cortexolona na forma cristalina de hidrato iv
TWI250158B (en) Crystal modification of lipoic acid
US2736681A (en) Chemical compounds
GB2107715A (en) Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
US4391755A (en) Steroid monohydrates, formulations containing same and method
KR100535305B1 (ko) 토실산 스프라타스트 결정
US4447426A (en) Steroid monohydrates, formulations containing same and method
US4435325A (en) 1α,25α-Dihydroxy-cholecalciferol and methods for the production thereof
JP2006160765A (ja) （±）２−（ジメチルアミノ）−１−｛〔Ｏ−（ｍ−メトキシフェネチル）フェノキシ〕メチル｝エチル水素サクシナート塩酸塩の結晶
JP2006160766A (ja) （±）２−（ジメチルアミノ）−１−｛〔Ｏ−（ｍ−メトキシフェネチル）フェノキシ〕メチル｝エチル水素サクシナート塩酸塩の結晶
CA1127655A (en) N-benzoyl-retinylamines, their preparation and pharmaceutical formulations containing these compounds
JP2006160764A (ja) （±）２−（ジメチルアミノ）−１−｛〔Ｏ−（ｍ−メトキシフェネチル）フェノキシ〕メチル｝エチル水素サクシナート塩酸塩の結晶
JP2677906B2 (ja) パラ−アミノベンゼンスルファニルアミドの物理的に安定した結晶性α−変態の調製方法
EP1070083B1 (de) Kristalline formen von 1s-[1alpha(2s*,3r*),9alpha]-6,10-dioxo-n- (2-ethoxy-5-oxo-tetrahydro-3-furanyl)-9-[[(1-isochinolyl)carbonyl]- amino]octahydro-6h-piridazino[1,2-a][1,2]diazepin-1-carboxyamid
HU210879A9 (en) Pharmaceutical agents
US3857941A (en) Pharmaceutical compositions and use of prednisolone 17-benzoate
EP0056465B1 (de) Pyrazolin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
EP0056466A2 (de) Pyrazolin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
CN114213485A (zh) 一种烟酰胺单核苷酸结晶的制备方法
TW201414722A (zh) 胺鹽及其結晶
JPH0123478B2 (de)

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 12